Ionis reports fourth quarter and full year 2023 financial re

WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year
Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE,...

Related Keywords

Canada , Elizabethl Hougen , , Astrazeneca , Novartis , Linkedin , Company Phase , Nasdaq , Ionis Pharmaceuticals , Foundation For Angelman Syndrome Therapeutics Summit , Akcea Therapeutics Inc , Ionis Pharmaceuticals Inc , Exchange Commission , Technology Advancement , Breakthough Therapy , Full Year , Fast Track , Breakthrough Therapy , Angelman Syndrome Therapeutics , Royalty Pharma , Serum Vitamin , Recommended Supplementation , Prescribing Information , Akcea Therapeutics , Consolidated Statements , Except Per Share Data , Consolidated Operating Expenses , From Operations , Net Income , Selected Financial Information , Data Events , Markets ,